Nyhet från partner

Adjutec applies for phase I start

Adjutec applies for phase I start

Norwegian AdjuTec Pharma prepares for clinical trials with its concept for battling antimicrobial resistance.

The company recently raised 16 MNOK and sent a clinical trial application to the swedish regulatory autorities, aming to start phase I this summer. BioStock contacted CEO Bjørn Klem to get an update.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

Denna källa har få eller inga artiklar bakom betalvägg
Läs hela texten hos Biostock

Nyhetsbrev